The Singapore-based company will debut a system at AACC that performs real-time PCR flu A/B testing in less than 20 minutes for the cost of a lateral flow test.
The Branford, Connecticut-based startup plans to seek US Food and Drug Administration clearance for and launch its instrument and first assays in 2021.
Blue Shield of California's members will be able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
NeuMoDx's tests are designed for central laboratory use and run on the company's fully automated NeuMoDx 96 or 288 real-time PCR systems.
The firm claims that its liquid biopsy platform can identify mutations in patient samples at femtogram-level concentrations.
UK researchers said they are developing a commercial test that could enable sensitive detection of tuberculosis DNA in blood and provide an option to broaden screening.
The firm had revenues of $6.32 billion in Q2, up 4 percent from $6.08 billion last year and just beating the average Wall Street estimate of $6.3 billion.
The test combines a genetic risk analysis with behavioral and lifestyle assessments, and uses Thermo Fisher Scientific's TaqMan OpenArray for genotyping.
Labs in China can now use the Cobas EGFR Mutation Test v2 with either tissue or plasma samples as a CDx for three Roche oncology drugs in NSCLC patients.
The test is designed to detect clinically relevant pathogens and markers of antibiotic resistance from bronchoalveolar lavage specimens.
The Dublin, Ireland-based company plans to launch its new instrument by the end of 2021 and will pursue CLIA waiver in the US.
Nationwide Labs will use the PathogenDx array system for rapid strain identification of skin and foot fungi.
The test could potentially enable labs to bring resistance testing in house, rather than send testing out to Canada's National Microbiology Laboratory.
The iC-GN Assay detects target DNA and identifies gram-negative organisms associated with gram-negative bacteremia, and three antibiotic-resistance markers.
The firm is applying the isolation tool in cellular therapy for oral cancer by administering a biomarker via bioengineered exosomes to reverse cancer progression.
The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.
Five hundred pharmacies will provide information about pharmacogenetic testing to members who have failed one or more antidepressant treatments.
Nasdaq told the company that its shares have failed to meet a minimum $1 per share closing price for 30 consecutive days and may face delisting action.
The companies will combine their respective technologies to offer genomic services for the plant and animal breeding sectors.
The group will integrate IDT's oligo synthesis technology with 3CR's PCR Allele Competitive Extension (PACE) Genotyping Master Mix and expertise in developing assays.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.